Key Takeaways
- Biotech IPOs raised $1.7bn in 2024, up 64% year-on-year.
- Alumis and Upstream Bio plan IPOs, leveraging investor enthusiasm.
- Market cautiousness due to potential Federal Reserve interest rate cuts.
What Happened?
Alumis and Upstream Bio, US start-ups focused on developing treatments for inflammatory diseases, have filed for IPOs. Alumis aims to leverage the $259 million raised earlier this year, valuing it around $1 billion. Upstream Bio’s lead drug, targeting severe asthma, is in mid-stage trials.
Despite the poor performance of 11 biotech listings this year, biotechs raised $1.7 billion through US IPOs in 2024, marking a 64% increase year-on-year, according to Dealogic. The IPO market, particularly for biotechs, has been slow to recover from the 2022 downturn, but recent months show signs of revival.
Why It Matters?
This surge in biotech IPOs signals renewed investor confidence in the sector. Biotechs raised $1.7 billion this year, a 64% increase from last year. The revival of follow-on deals, which rose over 100% to $16.5 billion, suggests a healthier market environment, encouraging new listings. Mike Perrone from RW Baird highlights that investor enthusiasm has tempered due to uncertainties around the Federal Reserve’s interest rate policies.
However, the strong performance of companies like CG Oncology, which saw an 80% rise post-IPO, indicates selective investor appetite for high-potential biotech stocks.
What’s Next?
Investors should monitor the timing of these IPOs closely, especially with the upcoming presidential election, which could impact market stability. Companies like Alumis and Upstream Bio, with promising drug candidates, are poised to attract significant attention.
Alumis, in particular, might see strategic interest from larger pharmaceutical companies due to its late-stage trials. The market’s cautious optimism suggests that while IPOs are on the rise, pricing will be crucial to attract new investors. The performance of upcoming listings will provide further insights into the sector’s trajectory and investor sentiment.
